After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...